Mechanism and rational combinations with <scp>GP</scp>‐2250, a novel oxathiazine derivative, in ovarian cancer
Taken together, our data indicate that GP-2250 exerts profound effects on tumor metabolism and, in combination with PARP inhibitors or bevacizumab, showed promising anti-tumor efficacy. These findings could have implications for the clinical development of GP-2250.
Authors
- Robert Louis Coleman (ORCID: https://orcid.org/0000-0001-9343-8754)
- Robiya Joseph (ORCID: https://orcid.org/0000-0003-3214-890X)
- Emine Bayraktar (ORCID: https://orcid.org/0000-0002-5189-1507)
- Adrian Lankenau Ahumada (ORCID: https://orcid.org/0000-0002-1490-7311)
- Deanna Glassman (ORCID: https://orcid.org/0000-0003-4591-8272)
- Mark S. Kim (ORCID: https://orcid.org/0000-0003-1959-3259)
- Katherine Foster (ORCID: https://orcid.org/0000-0001-7714-246X)
- Katelyn F. Handley (ORCID: https://orcid.org/0000-0002-3020-5731)
- Sanghoon Lee (ORCID: https://orcid.org/0000-0001-8564-2392)
- Anil K. Sood (ORCID: https://orcid.org/0000-0003-4242-1762)
- Nicholas B. Jennings (ORCID: https://orcid.org/0000-0003-0357-2920)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of South Florida (US)
- Moffitt Cancer Center (US)
- The US Oncology Network (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/cam4.70031
- Citations
- 2
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute